含有光敏剂的人体皮肤的激光诱导荧光光谱分析  

Laser-Induced Fluorescence Analysis of Human Skin with Photosensitizer

作　　者：于常青[1] 刘杰[2] 窦晓鸣[1] 赵海鹰[1] 方为军[1] 袁波[1] 

机构地区：[1]上海交通大学物理系分子光子学研究室,上海200030 [2]北京联合大学师范学院电子信息系,北京100011

出　　处：《光谱学与光谱分析》2003年第6期1150-1153,共4页Spectroscopy and Spectral Analysis

基　　金：上海市科学技术委员会(o1DJGK013)资助项目

摘　　要：利用血红蛋白在578nm处有吸收峰以及在光动力疗法治疗鲜红斑痣过程中病变区血液含量减少的特性,根据测得的含有光敏剂的皮肤层激光诱导荧光光谱,计算了皮肤层光敏剂的荧光强度随时间的变化关系。通过光谱处理计算了624nm处光敏剂血卟啉(HpD)的荧光峰值强度。分析和计算结果表明,皮肤层中的血液含量的减少导致新的荧光光谱峰(578nm处)的产生,新荧光峰的产生造成624nm处荧光强度的增大,因此必须排除这种影响才能得到皮肤层由光敏剂产生的荧光强度。由光谱处理结果得到治疗过程中病变区光敏剂荧光强度的变化曲线。There is a gradually rising new fluorescence spectrum peak that appears at about 578 nm in the treatment of photodynamic therapy (PDT) of port wine stain (PWS) . The new fluorescence peak spreads to 700 nm and adds additional fluorescence intensity at 624 nm, the characteristic fluorescence peak of haematoporphyrin derivative (HpD). To measure the fluorescence intensity at 624 nm of HpD, a mathematic method was employed to reduce the influence of the new peak arising at 578 nm. The time-dependent fluorescence intensity of HpD within the skin was measured. Since the hemoglobin has an absorption spectrum peak at about 578 nm, we consider that the new fluorescence peak may be caused by the decrease of blood contained in the skin with PWS during PDT treatment.

关 键 词：光敏剂 人体 皮肤 血液 激光诱导荧光技术 荧光光谱分析 荧光强度 鲜红斑痣 光动力疗法 光敏药物 

分 类 号：R454.2[医药卫生—治疗学] R318.51[医药卫生—临床医学]